Medical professionals and tens of millions of hepatitis B patients hope to completely cure hepatitis B and remove the “hepatitis B virus”. Viral hepatitis B is caused by the hepatitis B virus that invades liver cells, survives and replicates in the liver cells, and infects more liver cells causing liver inflammation. During the infection of hepatocytes, the hepatitis B virus forms a complete loop of double-stranded DNA (i.e., cccDNA) within the hepatocytes, which is the source of hepatitis B virus replication. Once cccDNA is formed in the nucleus of the hepatocyte, it can remain in the hepatocyte for a long time. Currently, the medical community does not know why cccDNA is stable and its regulatory mechanism, resulting in the fact that there are no drugs that can act directly on cccDNA and therefore cannot completely eliminate the hepatitis B virus, but can only inhibit the replication of the hepatitis B virus through antiviral drugs. Currently, the only medically recognized antiviral drugs are interferon and nucleoside analogs (such as lamivudine, adefovir, telbivudine, entecavir, etc.). The hepatitis B virus is variable, mainly because it has different genotypes. On the other hand, in order to adapt to the environment of long-term mutual struggle with the human body and antiviral drugs, the hepatitis B virus will mutate, and the mutation can occur in different parts of the viral sequence for different individuals and different antiviral drugs. The mutation of the virus can reduce the effectiveness of clinical antiviral drug therapy. The existing treatments for hepatitis B in China are: antiviral, liver protection, enzyme lowering, immunomodulatory therapy, etc. Antiviral therapy can effectively inhibit hepatitis B virus replication, stop the development of liver inflammation and indirectly lower enzymes, and is therefore recognized as the key to hepatitis B treatment. There are still many difficulties in the implementation of antiviral therapy, one is that doctors’ expectations of antiviral therapy are too high or too low, etc.; two is that patients do not understand the importance of antiviral therapy and are satisfied with liver preservation and enzyme lowering; three is that the existing antiviral therapy drugs can only inhibit the replication of the virus, and the ultimate clearance of the virus depends on the patient’s own immune clearance function; four is that antiviral therapy is most suitable for patients with high transaminase levels Fourth, antiviral therapy is most suitable for patients with high transaminase levels and significant active inflammation of liver tissue; fifth, treatment regimens often need to be individualized, and sometimes repeated antiviral therapy is required; sixth, the cost of antiviral therapy is large, and the ability to pay is a real problem. To sum up, hepatitis B treatment is a long-term medical process, and each patient with chronic hepatitis B must go to a regular hospital for treatment under the guidance of an experienced specialist in order to be responsible for himself or herself and the next generation; at the same time, the doctor and the patient should maintain long-term contact, regular review and follow-up; only then can the doctor keep abreast of changes in the patient’s condition and his or her response to treatment, and implement effective comprehensive treatment. As for the individual reports of “eradicating hepatitis B in 3 months”, this is a scientific lie, so do not be fooled.